Therapeutic effect of Atractylenolide I on Aspergillus fumigatus keratitis by affecting MyD88/ NF-κB pathway and IL-1β, IL-10 expression

Chen, Xiaomeng; Lu, Danli; Liu, Wenting; Xie, Jianye; Lu, Zhenjun; Yang, Hua; Yan, Haijing; Wang, Limei; Che, Chengye

doi:10.1016/j.cyto.2022.156112

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to other researchers, ATL I and III can inhibit methicillin-resistant Staphylococcus aureus and have distinct antibacterial properties [ 113 ]. In addition, ATL I can also improve fungal keratitis by inhibiting the secretion of MyD88/NF-κB pathway and IL-1β and IL-10, and enhance the efficacy of natamycin [ 114 ].…”

Section: Pharmacological Effects Of Atractylenolidesmentioning

confidence: 99%

Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review

Xie

Lin

et al. 2023

Molecules

View full text Add to dashboard Cite

Atractylenolides, comprising atractylenolide I, II, and III, represent the principal bioactive constituents of Atractylodes macrocephala, a traditional Chinese medicine. These compounds exhibit a diverse array of pharmacological properties, including anti-inflammatory, anti-cancer, and organ-protective effects, underscoring their potential for future research and development. Recent investigations have demonstrated that the anti-cancer activity of the three atractylenolides can be attributed to their influence on the JAK2/STAT3 signaling pathway. Additionally, the TLR4/NF-κB, PI3K/Akt, and MAPK signaling pathways primarily mediate the anti-inflammatory effects of these compounds. Atractylenolides can protect multiple organs by modulating oxidative stress, attenuating the inflammatory response, activating anti-apoptotic signaling pathways, and inhibiting cell apoptosis. These protective effects extend to the heart, liver, lung, kidney, stomach, intestine, and nervous system. Consequently, atractylenolides may emerge as clinically relevant multi-organ protective agents in the future. Notably, the pharmacological activities of the three atractylenolides differ. Atractylenolide I and III demonstrate potent anti-inflammatory and organ-protective properties, whereas the effects of atractylenolide II are infrequently reported. This review systematically examines the literature on atractylenolides published in recent years, with a primary emphasis on their pharmacological properties, in order to inform future development and application efforts.

show abstract

Section: Pharmacological Effects Of Atractylenolidesmentioning

confidence: 99%